FDA OKs hot-flash drug from Pfizer, Ligand

10/4/2013 | Bloomberg

The FDA has granted Pfizer and Ligand Pharmaceuticals approval for their osteoporosis and hot-flash treatment Duavee. The medication is to be used in postmenopausal women who haven't had a hysterectomy and who suffer moderate to severe hot flashes. The drug is also indicated for prevention of post-menopausal osteoporosis.

View Full Article in:

Bloomberg

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ